These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12935941)

  • 41. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
    Gidwani M; Singh AV
    Curr Pharm Biotechnol; 2014; 14(14):1201-12. PubMed ID: 24809717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted drug delivery to the brain; (blood-brain barrier, efflux, endothelium, biological transport).
    Terasaki T; Pardridge WM
    J Drug Target; 2000; 8(6):353-5. PubMed ID: 11328661
    [No Abstract]   [Full Text] [Related]  

  • 43. Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy.
    Islam N; Abbas M; Rahman S
    CNS Neurol Disord Drug Targets; 2017; 16(3):303-310. PubMed ID: 27978796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation of drug transporters at the blood-brain barrier.
    Fricker G; Miller DS
    Pharmacology; 2004 Apr; 70(4):169-76. PubMed ID: 15001817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier.
    On NH; Miller DW
    Curr Pharm Des; 2014; 20(10):1499-509. PubMed ID: 23789953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting transporters for CNS drug delivery.
    Ronaldson PT
    Curr Pharm Des; 2014; 20(10):1419-21. PubMed ID: 23789947
    [No Abstract]   [Full Text] [Related]  

  • 47. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transport Across the Blood-Brain Barrier.
    Fu BM
    Adv Exp Med Biol; 2018; 1097():235-259. PubMed ID: 30315549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vector-mediated drug delivery to the brain.
    Temsamani J; Rousselle C; Rees AR; Scherrmann JM
    Expert Opin Biol Ther; 2001 Sep; 1(5):773-82. PubMed ID: 11728213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of caveolin-1 in the biology of the blood-brain barrier.
    Zhao YL; Song JN; Zhang M
    Rev Neurosci; 2014; 25(2):247-54. PubMed ID: 24501156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.
    Stenehjem DD; Hartz AM; Bauer B; Anderson GW
    Future Med Chem; 2009 Dec; 1(9):1623-41. PubMed ID: 21425983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?
    Abdullahi W; Davis TP; Ronaldson PT
    AAPS J; 2017 Jul; 19(4):931-939. PubMed ID: 28447295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of blood-brain barrier permeability.
    Rapoport SI
    J Drug Target; 1996; 3(6):417-25. PubMed ID: 8863135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanotechnologies: a strategy to overcome blood-brain barrier.
    De Rosa G; Salzano G; Caraglia M; Abbruzzese A
    Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How critical is the blood-brain barrier to the development of neurotherapeutics?
    Kut C; Grossman SA; Blakeley J
    JAMA Neurol; 2015 Apr; 72(4):381-2. PubMed ID: 25642802
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug transfer across the blood-brain barrier and improvement of brain delivery.
    Jolliet-Riant P; Tillement JP
    Fundam Clin Pharmacol; 1999; 13(1):16-26. PubMed ID: 10027084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants of passive drug entry into the central nervous system.
    Habgood MD; Begley DJ; Abbott NJ
    Cell Mol Neurobiol; 2000 Apr; 20(2):231-53. PubMed ID: 10696512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.